Severe psychiatric disorders such as schizophrenia, bipolar disorder and major depressive disorder are brain diseases of unknown origin. No biological marker has been documented at the pathological, cellular, or molecular level, suggesting that a number of complex but subtle changes underlie these illnesses. We have used proteomic technology to survey postmortem tissue to identify changes linked to the various diseases. Proteomics uses two-dimensional gel electrophoresis and mass spectrometric sequencing of proteins to allow the comparison of subsets of expressed proteins among a large number of samples. This form of analysis was combined with a multivariate statistical model to study changes in protein levels in 89 frontal cortices obtained postmortem from individuals with schizophrenia, bipolar disorder, major depressive disorder, and non-psychiatric controls. We identified eight protein species that display disease-specific alterations in level in the frontal cortex. Six show decreases compared with the non-psychiatric controls for one or more diseases. Four of these are forms of glial fibrillary acidic protein (GFAP), one is dihydropyrimidinase-related protein 2, and the sixth is ubiquinone cytochrome c reductase core protein 1. Two spots, carbonic anhydrase 1 and fructose biphosphate aldolase C, show increase in one or more diseases compared to controls. Proteomic analysis may identify novel pathogenic mechanisms of human neuropsychiatric diseases. Molecular Psychiatry (2000) 5, 142-149.
Introduction
Serious psychiatric disorders such as schizophrenia, bipolar disorder and major depressive disorder are brain diseases which are major causes of morbidity throughout the world. Epidemiological and pathological studies indicate a role for both genetic and environmental factors in the etiology and pathogenesis of these disorders, but specific disease-associated genes or pathogenic agents have not as yet been identified. There are, at present, no biological or pathological markers which are highly associated with specific psychiatric disorders.
Two-dimensional electrophoresis is an analytic method that can quantify the levels of individual pro-tein species in complex biological samples 1 and allows comparison between diagnostic groups. This technique has been applied to the limited study of brain tissues, 2, 3 and cerebrospinal fluids [4] [5] [6] [7] obtained from individuals with schizophrenia. Recent advances in image analysis, sequencing and other proteinomic techniques allow for the more detailed analysis of protein expression in biological samples. 8, 9 Recently, a large number of postmortem brain samples have been collected from well-characterized individuals with schizophrenia, bipolar disorder, and major depressive disorder as well as equivalent samples from matched, unaffected controls. The technique of two-dimensional gel electrophoresis was employed, followed by sequencing by electrospray mass spectroscopy to identify proteins that show varied levels in the frontal cortex of individuals with defined psychiatric disorders. The relationship of these proteins to clinical diagnosis and other clinical and demographic parameters was further evaluated by application of a multivariate statistical model. The conditions used allowed us to compare and evaluate the subset of proteins which were highly abundant, relatively soluble proteins with pIs between 4-7. These methods resulted in the identification of eight disease-related changes in protein levels in the frontal cortex region of individuals with serious psychiatric diseases.
Materials and methods

Source of brain tissue
Analyses were performed on 89 postmortem human brains obtained as part of the Stanley Foundation Brain Collection. The brains were collected from designated medical examiners with the permission of the families, processed, and stored at −70°C. Diagnoses were made by two senior psychiatrists, and used DSM-IV criteria based on hospital records and telephone interviews with family members. Brain tissue was analyzed from individuals with the following diseases: schizophrenia (n = 24), bipolar disorder (n = 23), major depressive disorder without psychotic features (n = 19), and unaffected controls (n = 23). Tissue used in these studies was obtained from the frontal cortex (Brodmann Area 10) of the cerebral hemisphere which had been frozen on collection.
Tissue homogenization Approximately 0.2 g of frontal lobe tissue was homogenized in 8 volumes solubilizing solution (2% NP-40 (Sigma, St Louis, MO, USA), 9 M urea (Gibco, Grand Island, NY, USA), 0.5 dithiothreitol, and 2% ampholytes (pH 8.0-10.5 Pharmacia, Piscataway, NJ, USA)) for 30 s using a Tissue Tearor at setting 2. The insoluble materials were removed by ultracentrifugation at 100 000 × g, 20°C, for 30 min. Homogenates were stored at −80°C until use.
Two-dimensional gel electrophoresis
Proteins were resolved by 2-D gel electrophoresis using the 20 × 25 cm ISO-DALT 2-D gel system operating with 20 gels per batch. All first-dimension isoelectric focusing gels were prepared using the same batch of ampholytes (BDH 4-8A, Gallard-Schlesinger, New York, USA). Three microliters containing roughly 100 g of solubilized brain protein were applied to each gel, and the gels run for 33 000-34 500 volt-hours using a progressively increasing voltage protocol implemented by a programmable high voltage power supply. The second dimension gels were prepared using an Angelique computer-controlled gradient casting system where the top 5% of the gel was 11% T acrylamide, and the lower 95% of the gel varied linearly from 11% to 18%. Second dimension slab gels were run in groups of 20 in thermostabilized (10°C) DALT tanks with buffer circulation.
Staining, scanning and image analysis
Slab gels were fixed and stained for protein using colloidal Coomassie Blue G-250 procedure. Staining proceeded for about 4 days in order to reach equilibrium intensity. Coomassie was chosen for being reproducibly quantitative as opposed to the equally sensitive Molecular Psychiatry fluorescent stains or the ten-fold more sensitive silver stain. Each slab gel was digitized in red light at 133-m resolution, using an Eikonix 1412 scanner. Each gel was then processed using the Kepler software system, procedure PROC008b, to yield a spotlist giving position, shape and density information for each spot detected.
Master pattern construction and normalization
A master 2-D pattern of human frontal cortex was constructed using multiple 2-D images which included the common polymorphisms and additional spots encountered in the full set of brain samples (Figure 1 ). Spots were all identified with a number. The individual gels were then matched back to the master in two steps. First, an experienced operator manually matched about 50 protein species with their corresponding numbers from the master pattern, creating a set of reference points. Subsequently, an automated program identified all other protein species based on their relation to the manually matched spots. All spots were normalized by the sum of the densities of a small set of spots which were well resolved and present in almost all gels. A parallel set of gels was co-run with a rat liver protein preparation, and the proteins of the well characterized rat liver proteome 10 were used as molecular weight and pI standards.
Statistical analyses
The levels of individual protein species (measured as described above) were predicted by variables representing diagnostic, demographic, lifestyle, mode of death, and subsequent tissue storage characteristics using a multivariate statistical model. Over 20 such variables are known on each of these brains. Because of strong correlations with one another (colinearity) as well as a need to limit variables due to the small number of samples, the number used in the model was reduced specifically to avoid colinearity between the independent variables. The final model contained the following 10 antemortem and postmortem dependent variables that could affect protein levels in brain tissue: age (years); alcohol use (scaled 0-5); drug abuse (scaled 0-5); death by carbon monoxide poisoning (yes/no); suicide other than carbon monoxide poisoning (yes/no); diagnosis (schizophrenic, bipolar, depressed, or unaffected); body mass index (kg/m 2 ); brain weight (g); freezer storage interval (months); and pH of occipital lobe. Alcohol and drug abuse scales and the pH measurement methods have been described previously.
11
Protein sequence determination Proteins of interest were excised from the two-dimensional gels, digested with trypsin in situ and peptides were eluted and subjected to and sent for sequencing by electrospray mass spectrometry. The deduced peptide sequence(s) was compared against the Swiss protein database for known matches.
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Figure 1
Master pattern of 2-D gels. A compilation of spots found on all 89 gels, with pI and molecular weight scales deduced by co-localization with rat liver standards as described in Materials and Methods.
Results
Matching and analysis of spots
A total of 217 spots were matched between all 89 gels. These proteins were quantified as described in Materials and methods. The resulting protein quantities were then analyzed in a multivariate model to eliminate the possible confounding effects of 10 different pre-and postmortem factors on the expression levels of the individual protein species.
Multivariate analysis showed that the quantities of eight distinct spots were independently related to one or more psychiatric diagnoses. Six of these (Nos. 74, 76, 119, 141, 311, and 500) exhibited a decreased level in the brains of individuals with psychiatric disorders as compared to unaffected controls while two proteins (Nos. 182 and 226) displayed increased levels compared to controls (Table 1 and Figure 2 ). The actual measurements of these proteins are displayed in Figure 3 . This univariate analysis does not correct for the pre-and postmortem factors included in the multivariate analysis, and therefore the P values are different and usually higher than those reported in Table 1 . These eight proteins were eluted from the 2-D gels, and tryptic peptides derived from them were sequenced by electrospray mass spectometry. The sequenced peptides were identified against known proteins in protein databanks (Table 2) .
Sequence identification of proteins
Four of the protein species (76, 119, 311, and 500) that were decreased in one or more diseases were identified as glial fibrillary acidic protein (GFAP). These four spots make up the majority of a 5-6 spot charge series visible on the two-dimensional gels (Figure 2, inset) . The pI and MW values of these spots are depicted in comparison to the theoretical values of the GFAP in Table 3 . The center spot, 189, had been previously identified as GFAP (data not shown) and its level was not significantly altered in any of the disease states.
There were four additional protein species with diagnosis-related alterations in frontal cortex expression ( Table 2 ). The core 1 protein of the ubiquinone cytochrome c reductase complex was significantly decreased and carbonic anhydrase I was significantly increased in the frontal cortex regions of individuals with depression. The pyrimidine-metabolizing enzyme dihydropyrimidinase-related protein 2 was decreased in individuals with schizophrenia, bipolar disorder, and major depressive disorder. A single spot containing both fructose biphosphate aldolase C and aspartate amino transferase was found to be increased in all three diseases.
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Discussion
Eight protein species displayed differences in levels which were strongly associated with at least one clinical diagnosis. The relationship between these statistically significant changes and disease were revealed by Molecular Psychiatry Figure 3 Box and whisker plots of protein levels for various diseases. Levels are measured in relative units as described in Materials and Methods. Boxes are drawn from the 12th to the 75th percentile of the data, with the median indicated by the line across the indentation. Error bars from the 5th to 95th percentile are also shown. ANOVA values measure the statistical differences between all groups, and were calculated on Statistica software. Theoretical values were obtained by entering the amino acid sequence P14136 into the pl/MW calculator at http://expasy.hcuge.ch/chzd/pi tool.html using large sample sets combined with multivariate analysis to account for individual variation and a number of confounding pre-and postmortem factors. The conditions used to run, stain and analyze the gels allow us to study a only a small subset of all available proteins, namely the highly abundant, soluble proteins with pIs between 4-7. Despite this limitation, the identification of these proteins gives us preliminary leads into possible pathways or processes involved in these diseases. For example, there was a decrease in the expression of dihydropyrimidinase-related protein 2 (DRP-2) in the brains of individuals with schizophrenia, bipolar disorder, and major depressive disorder. The animal homologs of DRP-2 (rat CRMP-62, mouse unc-33, chick TOAD-64) are brain-specific enzymes which play a crucial role in development. [12] [13] [14] [15] In humans, an absence of dihydropyrimidinase itself causes severe neurological impairments occurring through delayed or arrested development, and neuronal degeneration with secondary delay of myelinMolecular Psychiatry ation. 16, 17 Altered levels of DRP-2 protein are thus consistent with alterations in brain development which may play a role in a wide range of neurological and psychiatric disorders.
There was a significant increase in the level of carbonic anhydrase I in the brains of individuals with depression. Carbonic anhydrase I is the erythrocyte form of the enzyme, while its isoform, carbonic anhydrase II, is expressed in glial cells, myelin and choroid plexus [18] [19] [20] and is also one of the principal determinants of pH fluxes within neural cells. 21 This finding is of interest in light of the report of Hayes 18 who found that treatment with the carbonic anhydrase inhibitor acetazolamide resulted in a significant improvement in symptoms in individuals in the depressive phase of bipolar disorder. Levels of carbonic anhydrase should be evaluated in other brain areas in an attempt to determine the potential utility of therapeutic interventions directed at altering the levels of this activity.
There were also increased levels of brain-specific fructose-biphosphate aldolase C in the samples obtained from individuals with schizophrenia, bipolar disorder, and unipolar depression. Others have also found aldolase abnormalities in psychiatric disease. Aldolase immunoreactivity was elevated in CSF, 22 the activity was increased in the serum of psychiatric patients in a clinical state-dependent manner [23] [24] [25] [26] and was also abnormal in their first-degree relatives. 26 Further study of this phenomenon is warranted. Mass spectrometry sequencing of the same protein spot revealed peptides identified as aspartate aminotransferase. It appears that this protein is not expressed in brain, 27 and that it is most likely a contaminant in the preparation.
There was a statistically significant decrease in the levels of the core protein 1 of the mitochondrial ubiqui-nol-cytochrome c reductase complex in the brains of individuals with depression. Subtractive cDNA libraries (Johnston-Wilson and Yolken, unpublished observations) 28 show an excess of mitochondrial messages in the brains of some individuals with schizophrenia. The role of these mitochondrial enzymes in the etiology of psychiatric disorders deserves additional consideration.
Four of the eight protein species with diseasespecific differences on expression were identified as isoforms of the astrocytic glial fibrillary acidic protein (GFAP). The finding of multiple species of GFAP with different isoelectric points but similar molecular weights is probably a reflection of the presence of different levels of post-translational modification of this brain protein. Other researchers have also identified modified forms of GFAP using two-dimensional electrophoretic methods. 2, [29] [30] [31] The level of GFAP expression is modulated by many factors including cytokines, hormones and growth factors throughout brain development. 32, 33 GFAP can be phosphorylated at five sites (Thr7, Ser8, Ser13, Ser17 and Ser38) in response to numerous stimuli. 34 Phosphorylation results in the disaggregation of GFAP molecules 35 and results in a protein molecule with a greater negative charge. 36 Spots 311 and 500 may represent phosphorylated forms of the protein.
Alternatively, these species may represent other posttranslational modifications resulting in acetylation, glycosylation or deimination, 35 which would also generate molecules which migrate in a more acidic fashion on two-dimensional gels.
Several studies have compared GFAP levels in the brains of individuals with schizophrenia and unaffected individuals. No significant disease-related alterations in GFAP have been detected by in situ immunohistochemistry or by one-dimensional immunoblotting methodologies. 37 However, these methods would not be likely to detect differences related to phosphorylation or other post-translational modifications detectable by two-dimensional electrophoresis. Comings et al 1982, employing two-dimensional electrophoretic methods, found absences of some charge variant forms of GFAP in a small group of individuals with schizophrenia and depression (ෂ67% of analyzed samples) as compared to unaffected controls and other non-psychiatric neurological diseases (0-28%). 2 It is not known if the alterations in the levels of the GFAP isoforms have functional significance or whether they are a reflection of disease-specific alterations in pathways controlling post-translational modification. GFAP decreases have been documented in Down's syndrome 38 and in response to tumour necrosis factor ␣, basic fibroblast growth factor, and glucocorticoids in cell cultures. 32, 39 GFAP is known to increase dramatically in response to acute infection or neurodegeneration. 40 However, GFAP levels can be decreased in response to chronic infection with viruses such as pseudorabies, 41 varicella zoster, 42 and HIV-1. 43 Of particular interest in the case of HIV-1 is the finding that the viral envelope glycoprotein gp120 can directly inhibit the phosphorylation of GFAP. 44 The relationship between GFAP alterations, infections, and the pathophysiology of psychiatric diseases such as schizophrenia, bipolar disorder, and major depression is the subject of ongoing investigations.
Conclusion
The combination of two-dimensional electrophoresis, multivariate analysis and protein sequencing, has resulted in the identification of five proteins which are differentially expressed in the frontal cortex regions of the brains of individuals with psychiatric diseases. It is of note that some of these alterations were found in individuals with different psychiatric diagnoses and may represent features that are common to the different diseases such as non-specific markers of inflammation or a common second messenger pathway. The analyses of brain proteins by proteonomic methods is a way to identify disease-related changes in brain proteins and discover novel pathways for the diagnosis and treatment of serious human psychiatric diseases.
